AI Earnings: 2 Key Reports to Watch
But concerning notable companies reporting in the coming weeks, Palantir PLTR and NVIDIA NVDA reflect highly consequential reports concerning the AI frenzy.
Both stocks have enjoyed stellar growth over recent periods thanks to the red-hot demand, with many expecting the upcoming releases to further confirm the bullish trend.
For those interested in the AI frenzy, let's take a closer look at what analysts are expecting for each.
Palantir Reports August 4th
Palantir's latest set of quarterly results continued to impress, with sales climbing 40% year-over-year alongside an upgrade to its current-year sales outlook. Massive growth has been driven by red-hot demand that's seemingly only continuing to grow.
As shown below, the company's sales growth has been outstanding over recent periods, a reflection of the red-hot demand PLTR has been enjoying.
Importantly, customer count grew nearly 40% year-over-year and 8% sequentially. Palantir also booked a record U.S. commercial total contract value throughout the period ($810 million), which grew a staggering 180% year-over-year.
Customer growth will be the key metric to watch for the release, one that PLTR has consistently positively shocked on over recent periods. Analysts have been silent concerning their EPS and sales revisions, with expectations unchanged over recent months.
The AI-favorite is expected to see 55% EPS growth on 38% higher sales.
NVIDIA Reports August 27th
Unrelenting demand for its Data Center products has provided NVIDIA with unprecedented growth over recent years. The AI favorite again came out with rock-solid results in its latest quarterly print, with Data Center sales of $39.1 billion climbing 73% from the $22.5 billion print in the same period last year.
Below is a chart illustrating NVIDIA's Data Center sales on a quarterly basis. While the results themselves will (unsurprisingly) be the focal point of the release, commentary surrounding upcoming periods and new product launches will be a key post-earnings factor concerning share movement.
EPS revisions for NVDA's print have remained stagnant over recent months, with the current $1.00 Zacks Consensus EPS estimate suggesting 47% year-over-year growth. The $48.5 billion expected in sales is up a marginal 0.9% over the same timeframe, reflecting sizable YoY growth of 52%.
Bottom Line
The 2025 Q2 earnings cycle continues to roll along, with this week's reporting docket notably stacked. And concerning the broader AI frenzy, reports from NVIDIA NVDA and Palantir PLTR will be key in getting a better gauge on the current AI landscape.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
NVIDIA Corporation (NVDA): Free Stock Analysis Report
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 minutes ago
- Globe and Mail
If You Bought 100 Shares of IonQ at Its IPO, Here's How Much Money You'd Have Now
Key Points IonQ began trading on public markets in 2021 after merging with a special purpose acquisition company. Shares of IonQ have soared over the past four years. The stock has plenty of potential to continue rising as the quantum computing industry matures. 10 stocks we like better than IonQ › With the potential to revolutionize computing as we know it, quantum computing has soared in popularity among investors seeking tech stocks with ample growth opportunity. Of the limited number of quantum computing stocks, IonQ (NYSE: IONQ), a leader in the field, is one of the most recognizable names. But a stock growing in popularity doesn't always ensure that shares will also rise. Let's see how IonQ investors who bought shares four years ago after the company's debut on public markets have fared. The first quantum computing company on the scene Proclaiming itself the "first publicly traded, pure-play quantum computing company," IonQ began trading on Oct. 1, 2021 at $10.60 after the company completed a merger with a special purpose acquisition company (SPAC). Over the following years, the company has announced several notable achievements. From opening the first quantum computing manufacturing facility in the United States, to applying quantum computing to artificial intelligence (AI) and machine learning that advances hybrid quantum-classical computing to improve both large language models and generative AI, IonQ has made tremendous strides that have excited investors' interest. As a result of the company's progress, shares of IonQ have soared. People who invested $1,060 to buy 100 shares at the stock's open on the first day of trading at it's opening price had seen their positions grow to $4,122 as of the end of trading on Aug. 6, 2025. Is it a quantum leap to think that IonQ stock can rise further? As a leader in the burgeoning quantum computing field, IonQ stock is one of the most common considerations for investors seeking exposure to the cutting-edge technology. While quantum computing might seem the stuff of science fiction, the company is demonstrating that there's nothing fictitious about the technology. As it pursues integrating its technology with hyperscalers like Microsoft Azure and Amazon Web Services, the company has robust growth potential over the coming years, and there's the definite potential for IonQ stock to continuing surging higher. Should you invest $1,000 in IonQ right now? Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $619,036!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,092,648!* Now, it's worth noting Stock Advisor's total average return is 1,026% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
11 minutes ago
- Globe and Mail
ER+/ HER2-VE Breast Cancer Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'ER positive, HER2 negative Breast Cancer Pipeline Insight 2025' report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in ER positive, HER2 negative Breast Cancer pipeline landscape. It covers the ER+/ HER2 -ve Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ER+/ HER2 -ve Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive ER+/ HER2 -ve Breast Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report In August 2025, Yale University announced a phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Patients with ER+ breast cancer anatomic stage IIB or III at diagnosis who are at least five years from diagnosis and have completed intended course of adjuvant endocrine therapy and are currently off endocrine therapy will be screened with ctDNA testing. In July 2025, Atossa Therapeutics Inc. announced a study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part. DelveInsight's ER+/ HER2 -ve Breast Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for ER+/ HER2 -ve Breast Cancer treatment. The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. Promising ER+/ HER2 -ve Breast Cancer Therapies such as Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others. Discover how the ER+/ HER2 -ve Breast Cancer treatment paradigm is evolving. Access DelveInsight's in-depth pipeline Analysis for a closer look at promising breakthroughs @ ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies Camizestrant: AstraZeneca Camizestrant, is a next-generation oral selective estrogen receptor degrader (SERD), as a promising treatment for ER-positive, HER2-negative breast cancer. This drug, developed by AstraZeneca, and has shown significant potential in improving progression-free survival (PFS) compared to the standard treatment with fulvestrant, which has been the mainstay therapy for almost two decades. Camizestrant has demonstrated significant efficacy in clinical trials, particularly the SERENA-2 phase II trial. In this study, camizestrant was compared to fulvestrant, a well-established treatment. Patients receiving camizestrant showed improved progression-free survival (PFS) at doses of 75 mg and 150 mg, with median PFS of 7.2 and 9.2 months, respectively, compared to 3.7 months for those on fulvestrant. This trial also highlighted camizestrant's ability to reduce ESR1-mutant circulating tumor DNA, indicating a strong efficacy in combatting endocrine-resistant tumors. Safety profiles from these studies indicate that camizestrant is generally well-tolerated, with manageable side effects such as fatigue, anemia, and mild visual disturbances. The favorable balance between efficacy and safety has supported the advancement of camizestrant into further phase III trials, like SERENA-4 and SERENA-6, which are exploring its use in combination with CDK4/6 inhibitors for broader clinical application. Currently, the drug is in Phase III stage of its development for the treatment of HER2-negative breast cancer. (Z)-endoxifen: Atossa Therapeutics, Inc. (Z)-endoxifen is the most active metabolite of the FDA approved Selective Estrogen Receptor Modulator (SERM), tamoxifen. Studies have demonstrated that the therapeutic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifen. In addition to its potent anti-estrogen effects, (Z)-endoxifen at higher concentrations has been shown to target PKCβ1, a known oncogenic protein. (Z)-endoxifen also appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. Atossa is developing a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach as acidic conditions in the stomach convert a greater proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa's (Z)-endoxifen has been shown to be well tolerated in Phase I studies and in a small Phase II study of women with breast cancer. Currently, the drug is in Phase II stage of its development for the treatment of ER-positive, HER2-negative breast cancer. AC699 is a potent and selective orally bioavailable, chimeric degrader of estrogen receptor (ER) α, and offers a potential new breast cancer treatment option based on a differentiated mechanism of action as compared to fulvestrant and novel SERDs with deeper ERα degradation as demonstrated in preclinical studies. AC699 is currently being evaluated in an ongoing Phase I clinical study as a single agent for the treatment of ER-positive / HER2-negative locally advanced or metastatic breast cancer. The primary objectives are to evaluate the safety and tolerability of AC699. Secondary and exploratory objectives include pharmacokinetics, preliminary efficacy and pharmacodynamic evaluation. The study uses a 3+3 dose-escalation design, with once-daily oral dosing of AC699 at 100, 200, 300, 400, and 600 mg. The ER+/ HER2 -ve Breast Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of ER+/ HER2 -ve Breast Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ER+/ HER2 -ve Breast Cancer Treatment. ER+/ HER2 -ve Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. ER+/ HER2 -ve Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ER+/ HER2 -ve Breast Cancer market. Get a detailed analysis of the latest innovations in the ER+/ HER2 -ve Breast Cancer pipeline. Explore DelveInsight's expert-driven report today! @ ER+/ HER2 -ve Breast Cancer Unmet Needs ER+/ HER2 -ve Breast Cancer Companies AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical ER+/ HER2 -ve Breast Cancer Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming ER+/ HER2 -ve Breast Cancer Therapies and key developments @ ER+/ HER2 -ve Breast Cancer Market Drivers and Barriers, and Future Perspectives Scope of the ER+/ HER2 -ve Breast Cancer Pipeline Report Coverage- Global ER+/ HER2 -ve Breast Cancer Companies- AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. ER+/ HER2 -ve Breast Cancer Therapies- Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others. ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in ER+/ HER2 -ve Breast Cancer drug development? Find out in DelveInsight's exclusive pipeline Report—access it now! @ ER+/ HER2 -ve Breast Cancer Emerging Drugs and Major Companies Table of Content Introduction Executive Summary ER+/ HER2-VE Breast Cancer: Overview Pipeline Therapeutics Therapeutic Assessment ER positive, HER2 negative Breast Cancer– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Camizestrant: AstraZeneca Drug profiles in the detailed report….. Mid Stage Products (Phase II) (Z)-endoxifen: Atossa Therapeutics, Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) AC699: Accutar Biotechnology Inc Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products ER+/ HER2-VE Breast Cancer Key Companies ER+/ HER2-VE Breast Cancer Key Products ER+/ HER2-VE Breast Cancer- Unmet Needs ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion ER+/ HER2-VE Breast Cancer Analyst Views ER+/ HER2-VE Breast Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
30 minutes ago
- Globe and Mail
ESAB (ESAB) Q2 Revenue Jumps 6%
Key Points Revenue (GAAP) exceeded expectations in Q2 2025, reaching $715.6 million, driven by acquisitions, compared to the estimated $674.5 million. Core adjusted EBITDA margin (non-GAAP) reached a record 20.4% in Q2 2025, reflecting ongoing margin improvement despite soft organic sales, particularly in the Americas. Full-year guidance was raised, with management now forecasts total core net sales growth of 1.5–3.5% for full year 2025 and higher targets for core adjusted EBITDA and core adjusted EPS for FY2025. These 10 stocks could mint the next wave of millionaires › ESAB (NYSE:ESAB), a leading global provider of fabrication technology and gas control solutions, reported Q2 2025 results on August 6, 2025. The most notable headline: GAAP revenue for Q2 2025 was $715.6 million, Q2 2025 GAAP revenue of $716 million exceeded analysts' estimates by $41.48 million, or 6.15%, while non-GAAP EPS of $1.36 matched consensus, while core adjusted earnings per share (non-GAAP) for Q2 2025 was $1.36, matching expectations. Management further raised its full-year 2025 guidance for core adjusted EBITDA and core adjusted EPS, boosted by contributions from recent acquisitions and robust business in EMEA (Europe, Middle East, Africa) and Asia-Pacific. Despite these positives, underlying organic growth was subdued in Q1 2025 and volumes in the Americas segment declined, offset only partly by price increases and product mix improvements. The period highlighted successful execution on margin expansion and strategic M&A, supporting a solid quarter for the company. Metric Q2 2025 Q2 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) $1.36 $1.36 $1.32 3.0% Revenue (GAAP) $715.6 million $674.5 million $707.1 million 1.2% Core Adjusted EBITDA Margin 20.4% 20.1% 0.3 pp Adjusted Free Cash Flow (Non-GAAP) $46.4 million $78.8 million (41.1%) Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. ESAB's Business and Current Focus Areas ESAB operates in the global fabrication technology market, supplying products like welding equipment, gas control equipment, consumables, and related automation solutions. Its gas control business serves medical, industrial, and specialty sectors. The company has established a presence in roughly 150 countries, giving it broad geographic reach and exposure to diverse end markets. The business focuses on several key strategies: capturing share in high-growth regions such as India and Asia-Pacific, shifting its sales mix toward gas control and advanced welding equipment, and growing through acquisitions. It also invests heavily in research and development to produce new equipment and improve digital capabilities, and it implements the ESAB Business Excellence (EBX) system for operational improvement. Success factors include maintaining profitability as the portfolio shifts to higher-margin categories, integrating new acquisitions quickly, and managing global supply chains efficiently. Quarter Highlights: Performance, Strategy, and Developments During Q2 2025, ESAB delivered GAAP revenue above expectations, supported mainly by the contribution from newly acquired businesses. On an organic basis—excluding the impacts from acquisitions and currency—revenue declined by 2.2% in Q2 FY2025. This softness was most pronounced in the Americas, where Core sales (non-GAAP) fell 8.7% in Q2 2024. In the Americas, core sales fell 8.7%, with distribution channels showing caution due to tariff uncertainty and other factors. For example, Core sales in the Americas declined from $309.8 million in Q2 2024 to $282.7 million in Q2 2025 (core, excludes Russia), with Adjusted EBITDA (non-GAAP) for the Americas was $56.8 million in Q2 2025. In contrast, EMEA and Asia-Pacific stood out as sources of strength. Core sales in EMEA and APAC climbed 11.0% in Q2 2025, supported by continued robust demand in high-growth markets like India and the Middle East. Core sales in EMEA and APAC rose to $395.7 million in Q2 2025, with Core adjusted EBITDA margin (non-GAAP) expanded to 20.6% in Q2 2025, up from 19.5% in Q2 2024. The company credited both new product uptake and the positive contribution of recent acquisitions for the result. Notably, ESAB completed the purchases of DeltaP and Aktiv, which expand its medical gas control business, and signed an agreement to acquire EWM, a European specialist in heavy industrial and robotic welding equipment. Product innovation continued to be a focus. The company rolled out new welding equipment and gas control solutions, with management reporting 'strong traction' in sales channels. Gas control now represents 18% of total revenue, up from 10% just a few years ago (as stated by management in Q1 2025). Gas control products, which support precise delivery and regulation of gases in medical and industrial environments, are both faster-growing and higher-margin than the company average. Strategic acquisitions in this space, especially in Europe and India, are expected to increase gas control to 25% of total revenue by 2028. Management noted that EBITDA margins in this segment are already ahead of the 2028 target. This drop reflected higher inventory in the Americas, a move to protect the supply chain against possible tariff disruptions. Cash and equivalents (GAAP) totaled $258 million as of Q2 2025. Ongoing acquisition activity and proactive inventory builds did impact cash conversion for the quarter. Looking Ahead: Guidance and Investor Watchpoints Management raised its full-year 2025 outlook. It now expects total core net sales growth of 1.5–3.5% for 2025, with the midpoint of that range above its prior view of (1.0)–1.5%. The projected core adjusted EBITDA range is now $525–$535 million for FY2025, and Core adjusted EPS guidance was raised to $5.15–$5.30 for 2025. These improvements reflect the contribution from acquisitions and some relief from negative currency exchange, but Expectations for core organic growth remain unchanged at 0.0% to 2.0% for the full year 2025. The impact from recent deals—especially DeltaP, Aktiv, and the imminent EWM acquisition—is a key factor in the increased full-year 2025 guidance. Looking ahead, ESAB will need to deliver more tangible organic growth, particularly in the Americas, which continues to experience volume weakness and a cautious channel environment. Management expects negative mid-single-digit core volume growth in the Americas for FY2025. Investors should keep an eye on the pace of integration of new acquisitions and the progress of the gas control segment as it moves toward its 2028 target. Any prolonged softness in free cash flow, persistent tariff uncertainty in North America, or shortfalls in organic growth could become areas of concern. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
